Companion Animal Postoperative Pain Management Therapeutics Market Size & Share 2024 – 2032

Companion Animal Postoperative Pain Management Therapeutics Market Size

Companion Animal Postoperative Pain Management Therapeutics Market size accounted for USD 133.5 million in 2023 and is expected to showcase growth at a CAGR of 6.5% from 2024 to 2032. The growth of the market is driven by the increasing prevalence of surgical procedures in companion animals.

As pet ownership rises and veterinary care advances, there is a growing demand for effective pain management solutions post-surgery. For instance, according to the American Pet Products Association (APPA), pet ownership in the U.S. has reached 85 million, with millions of pets undergoing surgeries annually. This growing number of surgical interventions needs effective pain management, highlighting the importance of therapeutics in ensuring animal welfare and recovery.
 

Moreover, rising awareness among pet owners about the importance of postoperative pain management is a significant driver of market growth. With an increasing understanding of the ethical considerations and benefits of pain relief, pet owners are more inclined to seek veterinary care that includes comprehensive pain management plans. Furthermore, the regulatory landscape for veterinary medicines has become more favorable, encouraging the development and approval of new pain management products. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have streamlined approval processes and provided clear guidelines for veterinary therapeutics, facilitating market entry for new products.
 

The companion animal postoperative pain management therapeutics market refers to the segment of the veterinary pharmaceutical industry that focuses on the development, manufacturing, and distribution of medications and therapies specifically designed to manage pain in companion animals following surgical procedures.
 

Companion Animal Postoperative Pain Management Therapeutics Market Trends

• Rising awareness of animal welfare has emerged as a significant driver for the market.
   
• As pet owners increasingly recognize the importance of postoperative care, they are more likely to seek veterinary treatments and medications to manage their pets’ pain after surgical procedures. This trend is further amplified by the growing emphasis on animal welfare and the ethical treatment of pets, which is supported by various government regulations and guidelines.
   
• Moreover, the trend of pet humanization, where pets are treated as family members, has further amplified the importance of compassionate care. Pet owners are more inclined to invest in advanced postoperative pain management therapies, including pharmaceuticals and alternative treatments, to provide the best possible care for their pets. This shift in mindset has resulted in an increased willingness to pay for premium postoperative pain management drugs that offer enhanced efficacy and safety.
   
• Additionally, the role of veterinarians and animal welfare organizations in educating pet owners about the importance of pain management has been crucial. These professionals emphasize the ethical responsibility of minimizing animal suffering, which has led to a greater adoption of pain management practices.
   
• As a result, rising awareness of animal welfare, coupled with the humanization of pets and the influence of veterinary guidance, has significantly contributed to the growth of the market.
   

Companion Animal Postoperative Pain Management Therapeutics Market Analysis

Based on the drug class, the market is categorized into NSAIDs, anesthetics, opioids, alpha-2 agonist, and other drug classes. The NSAIDs segment dominated the market with USD 103.7 million in 2023.
 

• Nonsteroidal anti-inflammatory drugs (NSAIDs) dominate the market due to their efficacy and safety profile in managing pain and inflammation in pets. NSAIDs account for a significant proportion of veterinary prescriptions, highlighting their importance in postoperative care.
   
• Their high market share is driven by broad acceptance among veterinarians, proven effectiveness in reducing pain and swelling, and a relatively low risk of severe side effects compared to other analgesics.
   
• The established track record of NSAIDs in clinical settings, combined with ongoing advancements in drug formulations, continues to reinforce their dominant position in the market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the companion animal postoperative pain management therapeutics market is segmented into oral, parenteral, and topical. The oral segment is dominated the market holding the highest market share of 57.1% in 2023.
 

• The oral segment holds a significant market share in the market due to its convenience, ease of administration, and effective pain relief.
   
• Oral therapeutics, including tablets, capsules, and oral suspensions, are preferred by veterinarians and pet owners for managing postoperative pain in companion animals because they simplify the administration process compared to injectable or topical treatments.
   
• Additionally, the growing awareness of pain management in veterinary care and advancements in oral drug formulations that offer improved efficacy and safety profiles contribute to the dominance of this segment in the market.
   

Based on the animal type, the companion animal postoperative pain management therapeutics market is segmented into dogs, cats, and other animal types. The dogs’ segment is projected to reach USD 159.7 million by 2032.
 

• Dogs hold a significant market share in the market, primarily due to their widespread status as household pets and the increasing awareness of their postoperative care needs.
   
• For instance, according to the American Pet Products Association (APPA), approximately 58 million U.S. households owned a dog in 2023, highlighting the substantial potential market for companion animal postoperative pain management therapeutics.
   
• Additionally, the high incidence of surgical procedures in dogs, including routine spaying, neutering, and more complex orthopedic or soft tissue surgeries, further boosts the segment's growth.
   

Based on the indication, the companion animal postoperative pain management therapeutics market is segmented into orthopedic surgery, soft tissue surgery, dental surgery, oncologic surgery, and other surgeries. The orthopedic surgery segment is expected to reach USD 86.9 million in 2032.
 

• Orthopedic surgery remains a leading segment in the market. This prominence is largely due to the increasing prevalence of musculoskeletal conditions, including arthritis and fractures, in companion animals. For instance, according to the National Institutes of Health (NIH), the number of companion animals undergoing orthopedic surgeries has increased and becoming more common over the past decade, indicating a significant demand for postoperative pain management therapeutics.
   
• Moreover, as pet owners seek advanced medical care for their animals, there is a growing demand for effective pain management solutions post-orthopedic procedures. This trend is driving innovation and adoption of multimodal analgesic protocols, including NSAIDs, opioids, and local anesthesia.
   
• Furthermore, the market's growth is also fueled by advancements in veterinary orthopedic techniques, such as arthroscopy, minimally invasive surgery which require precise pain management strategies to enhance recovery outcomes.
   

Based on distribution channel, the companion animal postoperative pain management therapeutics market is segmented into veterinary hospital pharmacies, retail pharmacies, and online pharmacies. The veterinary hospital pharmacies segment is expected to grow at the rate of CAGR 6.4% over the forecast period.
 

• Veterinary hospital pharmacies play an important role in the market. These pharmacies, situated within veterinary clinics and hospitals, provide specialized medications tailored to the unique needs of postoperative care for animals. They are integral to ensuring the safe and effective administration of pain management therapies, as they work closely with veterinarians to dispense medications, offer dosage guidance, and monitor patient responses.
   
• Also, Veterinary hospital pharmacies often stock a comprehensive range of pharmaceuticals including controlled substances, which are crucial for managing acute pain in postoperative scenarios. The availability of these medications on-site ensures that animals receive timely and appropriate pain relief, minimizing discomfort and facilitating a smoother recovery process.
   

The U.S. dominated the North American companion animal postoperative pain management therapeutics market accounting for USD 59.2 million in 2023 and is anticipated to show significant growth over the analysis period.
 

• North America holds a dominant position in the market, driven by a combination of advanced veterinary care infrastructure, high pet ownership rates, and significant investments in research and development.
   
• The region's robust healthcare system and widespread adoption of innovative pain management solutions contribute to its high market share.
   
• Furthermore, the increasing focus on enhancing the quality of life for pets, coupled with growing awareness among pet owners about effective pain management options, bolsters demand for advanced therapeutics.
   

UK exhibited a high growth potential in the European companion animal postoperative pain management therapeutics market.
 

• In the UK, the market has evolved considerably, reflecting the nation's strong commitment to animal welfare. The market is characterized by a growing demand for advanced pain relief solutions, spurred by the increasing number of surgical procedures performed on pets
   
• Additionally, the country’s stringent regulatory environment ensures high standards of care and safety in veterinary therapeutics, promoting the use of approved and tested medications. In addition, the market benefits from a well-established veterinary infrastructure and the strong support from government organizations.
   

The Asia Pacific companion animal postoperative pain management therapeutics market is poised for rapid growth with a CAGR of 7% during the forecast period.
 

• The Asia Pacific market is rapidly expanding, fueled by rising disposable incomes and the growing trend of pet adoption.
   
• The market is characterized by a diverse range of products, including traditional and innovative postoperative pain management solutions.
   
• Furthermore, the market's growth is also supported by supportive government initiatives aimed at improving animal health infrastructure and regulatory oversight.
   

Companion Animal Postoperative Pain Management Therapeutics Market Share

The market is driven by continuous innovation and technological advancements. Leading companies in the market offer a diverse range of advanced pain management solutions, including medications and therapeutic interventions, aimed at alleviating postoperative pain in companion animals. These companies consistently invest in research and development to introduce new formulations and improve existing products, thereby enhancing efficacy and safety of treatments and to maintain a competitive edge in the market.
 

Companion Animal Postoperative Pain Management Therapeutics Market Companies

Few of the prominent players operating in companion animal postoperative pain management therapeutics industry include:

• Assisi Animal Health
• Bayer AG
• Bimeda Animal Health
• Boehringer Ingelheim International GmbH
• Ceva Sante Animale
• Chanelle Pharma Group
• Dechra Pharmaceuticals
• Elanco Animal Health Incorporated
• Merck Animal Health
• Norbrook
• SAVA Vet
• Vetoquinol S.A.
• Virbac Group
• Zoetis Inc.
   

Companion Animal Postoperative Pain Management Therapeutics Industry News:

• In January 2024, Ceva Sante Animale acquired Scout Bio. With this strategic move, the company plans to expand its portfolio including companion animal postoperative pain management therapeutics with innovative solutions, driving growth through advanced biotechnologies. This strategy is expected to improve the company’s competitive position and market reach.
   
• In May 2023, Zoetis received approval of Librela from U.S. FDA to control osteoarthritis pain in dogs. Librela is the first and only once-monthly, osteoarthritis pain treatment for dogs. This strategy has added value to the company’s business portfolio.
   

The companion animal postoperative pain management therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• NSAIDs
• Anesthetics
• Opioids
• Alpha-2 agonists
• Other drug classes

Market, By Route of Administration

• Oral
• Parenteral
• Topical

Market, By Animal Type

• Dogs
• Cats
• Other animal types

Market, By Indication

• Orthopedic surgery
• Soft tissue surgery
• Dental surgery
• Oncologic surgery
• Other surgeries

Market, By Distribution Channel

• Veterinary hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa